Lundbeck presented data from the TALISMAN study and AMULET trial of amlenetug for multiple system atrophy (MSA) at the ...

San Diego start-up 858 Therapeutics has raised $50 million in a Series B round led by Avidity Partners, with participation from new and existing investors. The funds will advance 858’s pipeline, ...

Repair Biotechnologies has partnered with Genevant Sciences to combine its Cholesterol Degrading Platform (CDP) mRNA ...

Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...

Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more ...

Enanta Pharmaceuticals announced positive topline results from a Phase IIa trial of EDP-323, its RSV replication inhibitor, ...

Sage Therapeutics announced that Biogen has ended its partnership on the SAGE-324 program after the drug failed in a Phase II ...

European Commission (EC) has issued a marketing authorization for FYB202/Otulfi, a biosimilar to Johnson & Johnson’s Stelara.

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open ...

The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.